

AmideBio

FOR IMMEDIATE RELEASE

Contact:

Misha Plam

President & CEO

AmideBio, LLC

misha.plam@amidebio.com

(303) 641-3669

<http://www.AmideBio.com>

Boulder's AmideBio moves to new location

Boulder, CO June 16, 2011 -- AmideBio, LLC, which is focused on the production and commercialization of technically-challenging peptides for the R&D, clinical and therapeutic marketplaces, today announced that company operations have been consolidated from multiple locations in Boulder and Denver, CO., and re-located to the Colorado Technology Center in Louisville, CO.

AmideBio's new facility is located at 331 South 104 St, Louisville, CO 80027, the former location of Inverness Medical. In this facility, the company will continue optimization of multiple peptide products utilizing AmideBio's innovative chemical and recombinant hybrid manufacturing technology.

Michael Stowell, Ph.D. and Misha Plam founded AmideBio with an exclusive license to technology invented at the University of Colorado at Boulder. The company has already successfully manufactured research grade peptides utilizing this technology. Therapeutic peptides and biosimilar product candidates are also in active development.

According to Plam, "We are pleased with our move to CTC in Louisville, and intend to make good use of the existing biochemistry labs. This will allow us to scale up production, and will also provide adequate space for future expansion". AmideBio was represented in the lease transaction by Boulder Broker Geoffrey Keys of Keys Commercial Real Estate.

Primary advantages of the AmideBio hybrid manufacturing technology include lowering the cost of peptides for the research community, thereby enabling increased discovery efficiencies; compressing development and manufacturing time for clinical and therapeutic products, thereby enabling new peptide biologics that are difficult to manufacture with conventional methods; and improving production efficiencies and reducing the cost of cGXP-grade therapeutics, thereby enabling the rescue of therapeutic candidates that have failed in development due to the inability to establish viable processes to support preclinical and clinical studies.

About AmideBio, LLC

AmideBio, formerly based in Boulder, CO, is a biotechnology company focused on providing peptide research and clinical products for a diverse array of research and commercial targets. AmideBio addresses the challenges of historically difficult to manufacture peptides by using its proprietary technology to minimize toxicity during bacterial growth and in the chemical synthesis waste-stream, thereby simplifying downstream processing and reducing overall costs of development and manufacturing. AmideBio emphasizes the application of economically sensitive and environmentally sustainable practices. For more information please visit <http://www.AmideBio.com>